The UK health regulator rejected a new Alzheimer's drug despite it having passed an examination by the Medicines and Healthcare products Regulatory Agency. The National Institute for Health and Care Excellence announced that it was too expensive and had too little benefit to gain usage on the NHS against the backdrop of its success in …














